Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was the recipient of some unusual options trading on Friday. Stock investors bought 949 put options on the company. This is an increase of 868% compared to the average volume of 98 put options.

Shares of Jazz Pharmaceuticals (JAZZ) opened at $135.53 on Monday. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals has a 1 year low of $104.82 and a 1 year high of $163.75. The firm has a market capitalization of $8,125.16, a price-to-earnings ratio of 17.01, a P/E/G ratio of 0.87 and a beta of 0.98.

A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Sunday, December 10th. B. Riley reissued a “buy” rating and set a $206.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 5th. Mizuho increased their target price on Jazz Pharmaceuticals from $144.00 to $150.00 and gave the stock a “neutral” rating in a report on Tuesday, December 5th. Zacks Investment Research lowered Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Finally, HC Wainwright reissued a “neutral” rating and set a $150.00 target price (up from $144.00) on shares of Jazz Pharmaceuticals in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $181.28.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 9,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $139.73, for a total value of $1,257,570.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,552 shares of company stock worth $2,549,643. Insiders own 4.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank lifted its position in shares of Jazz Pharmaceuticals by 12.4% during the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares during the last quarter. US Bancorp DE lifted its position in shares of Jazz Pharmaceuticals by 94.4% during the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $211,000. Brighton Jones LLC bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $213,000. Finally, SG Americas Securities LLC lifted its position in shares of Jazz Pharmaceuticals by 13.0% during the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock worth $215,000 after buying an additional 159 shares during the last quarter. Institutional investors and hedge funds own 91.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Stock Traders Purchase High Volume of Put Options on Jazz Pharmaceuticals (JAZZ)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/18/stock-traders-purchase-high-volume-of-put-options-on-jazz-pharmaceuticals-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Stock Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related stocks with our FREE daily email newsletter.